- Home
- NBBK vs PRTA Comparison
NBBK vs PRTA Comparison
Compare NBBK & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- PRTA
- Stock Information
- Founded
- NBBK 1892
- PRTA 2012
- Country
- NBBK United States
- PRTA Ireland
- Employees
- NBBK N/A
- PRTA N/A
- Industry
- NBBK
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- PRTA Health Care
- Exchange
- NBBK Nasdaq
- PRTA Nasdaq
- Market Cap
- NBBK 687.7M
- PRTA 809.8M
- IPO Year
- NBBK N/A
- PRTA N/A
- Fundamental
- Price
- NBBK $18.76
- PRTA $6.40
- Analyst Decision
- NBBK Buy
- PRTA Buy
- Analyst Count
- NBBK 1
- PRTA 9
- Target Price
- NBBK $22.00
- PRTA $27.67
- AVG Volume (30 Days)
- NBBK 471.3K
- PRTA 1.8M
- Earning Date
- NBBK 07-23-2025
- PRTA 08-07-2025
- Dividend Yield
- NBBK N/A
- PRTA N/A
- EPS Growth
- NBBK 421.39
- PRTA N/A
- EPS
- NBBK 1.18
- PRTA N/A
- Revenue
- NBBK $169,131,000.00
- PRTA $137,935,000.00
- Revenue This Year
- NBBK N/A
- PRTA N/A
- Revenue Next Year
- NBBK N/A
- PRTA $119.20
- P/E Ratio
- NBBK $16.05
- PRTA N/A
- Revenue Growth
- NBBK 27.71
- PRTA 54.55
- 52 Week Low
- NBBK $14.84
- PRTA $4.32
- 52 Week High
- NBBK $21.05
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- NBBK 75.82
- PRTA 54.04
- Support Level
- NBBK $17.70
- PRTA $5.96
- Resistance Level
- NBBK $17.31
- PRTA $6.59
- Average True Range (ATR)
- NBBK 0.47
- PRTA 0.40
- MACD
- NBBK 0.27
- PRTA 0.18
- Stochastic Oscillator
- NBBK 90.91
- PRTA 79.56
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).